Danirixin [(S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea]
is a small, selective and reversible antagonist for C-X-C motif chemokine
receptor 2 (CXCR2, Interleukin 8 receptor, beta). It has high affinity for chemokine
(C-X-C motif) ligand 8 (CXCL8) with nanomolar potency (IC50 for
CXCL8 binding = 12.5 nM). The compound has demonstrated potent antagonism of
CXCR2 activity in vitro and
anti-inflammatory effects in various preclinical models [1, 2].
The pharmacologic activity and duration of action following oral administration supports Danirixin’s potential use as an oral, anti-inflammatory agent in the treatment of disorders associated with the accumulation of neutrophils especially in development for treatment of chronic obstructive pulmonary disease (COPD).
 |
| Danirixin: 2D and 3D Structure |
The pharmacologic activity and duration of action following oral administration supports Danirixin’s potential use as an oral, anti-inflammatory agent in the treatment of disorders associated with the accumulation of neutrophils especially in development for treatment of chronic obstructive pulmonary disease (COPD).
